GeneDx Holdings Corp.

Rosen Law Firm reminds purchasers of GeneDx Holdings Corp. common stock between April 16, 2025 and May 4, 2026 of the August 3, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that GeneDx made false and misleading statements about the impact of its Fabric acquisition on the company's financials and operations, and that investors suffered damages when the truth emerged. Investors with losses exceeding $100,000 are encouraged to secure counsel before the deadline. Rosen Law Firm notes that it has recovered billions of dollars for investors and was ranked number one by ISS Securities Class Action Services for settlements in 2017.

Faruqi & Faruqi, LLP reminds investors in GeneDx Holdings Corp. that the deadline to seek lead plaintiff appointment in a federal securities class action is August 3, 2026. The lawsuit alleges the company and its executives made false or misleading statements about the importance of the Fabric Genomics acquisition, the durability of average reimbursement rates, and the outlook for gross margins. On May 4, 2026, GeneDx reported first-quarter results that missed expectations, cut its 2026 revenue guidance from $540–$555 million to $475–$490 million, disclosed an average reimbursement rate of $3,300, and took a $31.3 million goodwill impairment charge on the Fabric Genomics acquisition it had purchased for $36.5 million a year earlier. The stock fell over 49%, or $33.42 per share, the following day. Investors who purchased or acquired GeneDx securities between April 16, 2025 and May 4, 2026 may contact the firm to discuss their legal rights.

Kahn Swick & Foti, LLC reminds investors that a securities class action lawsuit has been filed against GeneDx Holdings Corp. for alleged misrepresentations during the class period from April 16, 2025 to May 4, 2026. The lawsuit claims the company failed to disclose material information, and on May 4, 2026, GeneDx reported a drop in adjusted gross margin from 74% to 69%, missed revenue estimates for its exome and genome lines, and lowered full-year revenue guidance to $475–$490 million from $540–$550 million. The company also disclosed a $31.2 million impairment loss related to its prior acquisition of Fabric Genomics, which had been touted as a growth driver. Following the news, GeneDx shares fell $33.42, or 49.2%. Investors have until August 3, 2026 to file lead plaintiff applications.

Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against GeneDx Holdings Corp. in the United States District Court for the District of Connecticut on behalf of purchasers of WGS common stock between April 16, 2025 and May 4, 2026. The complaint alleges the company and its executives made false or misleading statements and failed to disclose issues including the importance of Fabric Genomics, declining margins, and less durable average reimbursement rates. On May 4, 2026, GeneDx reported a first quarter 2026 loss per share of $0.28 and a $57.5 million loss from operations, lowered its 2026 revenue guidance by approximately $65 million at the midpoint, and took a $31.3 million write-down related to Fabric Genomics goodwill and intangible assets. Following this news, GeneDx shares fell by $33.42 per share, or approximately 50%, from $67.93 on May 4, 2026 to close at $34.51 on May 5, 2026. Investors have until August 3, 2026 to apply to the Court to be appointed as lead plaintiff.

A securities fraud class action has been filed against GeneDx Holdings Corp., and investors who purchased shares between April 16, 2025 and May 4, 2026 have until August 3, 2026 to seek lead plaintiff appointment. The lawsuit alleges the company and certain executives made false statements about the benefits of acquiring Fabric Genomics, touting it as an AI-driven growth catalyst while concealing integration problems and operational disconnects. On May 4, 2026, GeneDx reported first-quarter results that missed revenue estimates, showed a drop in adjusted gross margins from 74% to 69%, slashed full-year 2026 revenue guidance to $475 million–$490 million from $540 million–$550 million, and recorded a $31.2 million impairment loss on Fabric Genomics, wiping out roughly 94% of the cash paid a year earlier. The stock then fell 49.2% in a single session, from $67.93 to $34.51. The law firm Hagens Berman is investigating and urging investors with substantial losses to contact them.

A securities fraud class action lawsuit has been filed against GeneDx Holdings Corp. over alleged misrepresentations about its acquisition of Fabric Genomics. The lawsuit, covering investors who purchased shares between April 16, 2025 and May 4, 2026, claims the company and certain executives made false statements about the strategic and financial benefits of the deal. GeneDx had touted Fabric as an AI-driven growth catalyst that would unlock recurring software revenue and reduce costs, but allegedly concealed significant integration problems and operational disconnects. On May 4, 2026, the company reported first-quarter results that missed revenue estimates, slashed full-year guidance to $475 million–$490 million from $540 million–$550 million, and recorded a $31.2 million impairment loss on Fabric, wiping out roughly 94% of the cash paid a year earlier. The stock plunged 49.2% the next day, from $67.93 to $34.51. Investors have until August 3, 2026 to seek lead plaintiff status.

Robbins Geller Rudman & Dowd LLP announced that purchasers of GeneDx Holdings Corp. common stock between April 16, 2025 and May 4, 2026 have until August 3, 2026 to seek appointment as lead plaintiff in a securities class action lawsuit. The lawsuit alleges that GeneDx and certain executives made false or misleading statements and failed to disclose significant problems with the viability of Fabric Genomics, which GeneDx had agreed to acquire on April 16, 2025. On May 4, 2026, GeneDx reported a drop in adjusted gross margin from 74% to 69%, reduced projected earnings from $540-$555 million to $475-$490 million, and a $31.3 million impairment loss directly attributable to Fabric Genomics, causing its stock price to drop over 49%. The lead plaintiff process allows any investor who purchased shares during the class period to seek appointment, and an investor's ability to share in any potential recovery is not dependent upon serving as lead plaintiff.

The Gross Law Firm has issued a notice to shareholders of GeneDx Holdings Corp. regarding a securities class action, with a lead plaintiff deadline of August 3, 2026. The class period runs from April 16, 2025 to May 4, 2026. The complaint alleges that the company made false and misleading statements about the Fabric acquisition, claiming it would improve financials and create efficiencies, while knowing of significant problems in Fabric's viability that would negatively impact overall business. Shareholders who purchased WGS shares during the class period are encouraged to contact the firm, though participation in any recovery does not require lead plaintiff appointment.

Kahn Swick & Foti, LLC reminds investors that a securities class action lawsuit has been filed against GeneDx Holdings Corp. for alleged misrepresentations during the class period from April 16, 2025 to May 4, 2026. The lawsuit claims the company failed to disclose material information, and on May 4, 2026, GeneDx reported a drop in adjusted gross margin from 74% to 69%, missed revenue estimates for its exome and genome lines, and lowered full-year revenue guidance to $475–$490 million from $540–$550 million. The company also disclosed a $31.2 million impairment loss tied to its prior acquisition of Fabric Genomics, an AI-driven genomic interpretation company that had been touted as a growth driver. On this news, GeneDx shares fell $33.42, or 49.2%. Investors who purchased shares during the class period have until August 3, 2026 to file lead plaintiff applications.

GeneDx Holdings Corp. shares detracted from performance after first-quarter results missed revenue expectations on softer average reimbursement rates and weakness in non-core segments. While underlying exome and genome test volumes grew 33% year over year, management lowered full-year guidance, weighing on investor sentiment. The company is a specialty genomics laboratory focused on delivering complex genetic tests, including whole exome and genome sequencing, to diagnose pediatric rare diseases. It possesses a comprehensive and proprietary database of genetic data that enables it to deliver superior diagnostic yields relative to competitors and alternative testing modalities, creating a meaningful competitive advantage in a highly specialized market.

A securities fraud class action lawsuit has been filed against GeneDx Holdings Corp. on behalf of investors who purchased or acquired WGS common stock between April 16, 2025, and May 4, 2026. The lawsuit, filed in the United States District Court for the District of Connecticut, alleges that the company made materially false and misleading statements regarding the viability of its acquisition of Fabric Genomics. GeneDx had announced the acquisition on April 16, 2025, in a deal worth up to $51 million, touting Fabric's AI-driven genomic interpretation platform as a source of scalable recurring revenue. On May 4, 2026, the company disclosed a $31.3 million impairment loss directly attributable to Fabric, representing nearly the entire upfront cash consideration, and its share price fell more than 49%. Investors have until August 3, 2026, to seek lead plaintiff status.

The Portnoy Law Firm has announced a class action lawsuit on behalf of investors who purchased GeneDX Holdings securities between April 16, 2025 and May 4, 2026. The complaint alleges the company and its executives made false or misleading statements and failed to disclose issues including the importance of Fabric Genomics, the durability of average reimbursement rates, and the impact on gross margins. On May 4, 2026, after the market closed, GeneDX reported first-quarter financial results that missed expectations for both its exome and genome lines and cut its 2026 revenue guidance from $540-555 million to $475-490 million. The company also disclosed an average reimbursement rate of $3,300, $200 below expectations, and a $31.3 million goodwill impairment charge related to the Fabric Genomics acquisition, which it had purchased for $36.5 million a year earlier. Following this news, GeneDX shares fell over 49%, or $33.42 per share, from the previous close. Investors have until August 3, 2026 to file a lead plaintiff motion.

Robbins Geller Rudman & Dowd LLP announced that purchasers of GeneDx Holdings Corp. common stock between April 16, 2025 and May 4, 2026 have until Monday, August 3, 2026 to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that GeneDx and certain top executives made false or misleading statements and failed to disclose significant problems in the viability of Fabric Genomics, which GeneDx agreed to acquire on April 16, 2025. On May 4, 2026, GeneDx reported a drop in adjusted gross margin from 74% to 69%, reduced projected earnings from $540-$555 million to $475-$490 million, and a $31.3 million impairment loss directly attributable to Fabric Genomics, causing the stock price to drop over 49%. The lead plaintiff will act on behalf of all class members and may select a law firm to litigate the case, though investors can share in any potential recovery without serving as lead plaintiff.

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GeneDx Holdings Corp. and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired GeneDx securities between April 16, 2025 and May 4, 2026. The complaint claims the company made false or misleading statements and failed to disclose that it may have misled investors about the importance of Fabric Genomics, that margins would suffer, that average reimbursement rates were not as durable as previously disclosed, and that gross margins would decline. Investors have until August 3, 2026 to seek lead plaintiff appointment. The firm represents investors on a contingency fee basis.

Faruqi & Faruqi, LLP reminds investors of the August 3, 2026 deadline to seek lead plaintiff in a securities class action against GeneDx Holdings Corp. The lawsuit alleges the company made false and misleading statements about its Fabric Genomics acquisition, the durability of average reimbursement rates, and gross margins. On May 4, 2026, GeneDx disclosed first-quarter results missed expectations, cut 2026 revenue guidance from $540-555 million to $475-490 million, reported average reimbursement rates of $3,300, and took a $31.3 million goodwill impairment charge on the Fabric Genomics acquisition it had purchased for $36.5 million a year earlier. The company's share price fell over 49%, or $33.42 per share, on the news. Investors who purchased GeneDx securities between April 16, 2025 and May 4, 2026 may contact the firm to discuss their legal rights.

Rosen Law Firm reminds purchasers of GeneDx Holdings Corp. common stock between April 16, 2025 and May 4, 2026 of the August 3, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that GeneDx made false and misleading statements about the impact of its Fabric acquisition on the company's overall business, causing investors to suffer damages when the truth emerged. Investors who purchased shares during the class period may be entitled to compensation through a contingency fee arrangement without out-of-pocket costs. A lead plaintiff must move the Court no later than August 3, 2026.

Hagens Berman is investigating claims in a securities class action lawsuit against GeneDx Holdings and its executives, alleging that investors were misled about the Fabric Genomics acquisition and its synergy potential. The investigation follows a 49% stock collapse on May 5, 2026, after the company reported a $31.2 million impairment charge related to the Fabric Genomics unit, which represented about 94% of the cash paid for it just one year earlier. The complaint alleges that GeneDx falsely touted the acquisition as a cornerstone of efficiency and future profitability, while the unit contributed to a tenfold increase in net loss and a $2.5 million revenue miss. The class period runs from April 16, 2025 to May 4, 2026, with a lead plaintiff deadline of August 3, 2026.

Bernstein Liebhard LLP announced that a securities class action lawsuit has been filed against GeneDx Holdings Corp. on behalf of investors who purchased or acquired common stock between April 16, 2025 and May 4, 2026. The lawsuit alleges that defendants made materially false and misleading statements about the company's business operations, growth prospects, and financial stability, causing the stock to trade at artificially inflated prices. When the truth was disclosed, investors allegedly suffered significant losses. Investors have until August 3, 2026 to file papers to serve as lead plaintiff.

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GeneDx Holdings Corp. and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired GeneDx securities between April 16, 2025 and May 4, 2026. The complaint claims the company made false and misleading statements and failed to disclose that it may have misled investors about the importance of Fabric Genomics, that margins would suffer, that average reimbursement rates were not as durable as previously disclosed, and that gross margins would decline. Investors have until August 3, 2026 to seek lead plaintiff appointment. The firm represents investors on a contingency fee basis.

A securities fraud class action lawsuit has been filed against GeneDx Holdings Corp. on behalf of investors who purchased or acquired WGS common stock between April 16, 2025, and May 4, 2026. The lawsuit, filed in the United States District Court for the District of Connecticut, alleges that the company made materially false and misleading statements regarding the viability of its acquisition of Fabric Genomics. On May 4, 2026, GeneDx announced a write-off of a $31.3 million impairment loss directly attributable to Fabric, which was only $5.2 million less than what it paid to acquire the firm a year prior, causing its share price to fall more than 49%. Investors have until August 3, 2026, to seek lead plaintiff status through counsel such as Kessler Topaz Meltzer & Check, LLP.

A securities class action lawsuit has been filed against GeneDx Holdings Corp. alleging that the company and certain executives failed to disclose material information, violating federal securities laws. Investors who purchased GeneDx shares between April 16, 2025 and May 4, 2026 have until August 3, 2026 to file lead plaintiff applications. The lawsuit follows a May 4, 2026 announcement where GeneDx reported a drop in adjusted gross margin from 74% to 69%, missed revenue estimates for its exome and genome lines, and lowered full-year revenue guidance to $475–$490 million from $540–$550 million. The company also disclosed a $31.2 million impairment loss related to its prior acquisition of Fabric Genomics, an AI-driven genomic interpretation company that had been touted as expanding the addressable market and transforming static data into a recurring revenue platform. On this news, GeneDx shares fell $33.42, or 49.2%.

Robbins Geller Rudman & Dowd LLP announced that purchasers of GeneDx Holdings Corp. common stock between April 16, 2025 and May 4, 2026 have until Monday, August 3, 2026 to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that GeneDx and certain top executives made false or misleading statements and failed to disclose significant problems with the viability of Fabric Genomics, which GeneDx agreed to acquire on April 16, 2025. On May 4, 2026, GeneDx reported a drop in adjusted gross margin from 74% to 69%, reduced projected earnings from $540-$555 million to $475-$490 million, and a $31.3 million impairment loss directly attributable to Fabric Genomics, causing the stock price to drop over 49%. Investors who suffered substantial losses can contact the firm to serve as lead plaintiff, though participation in any recovery does not require serving in that role.

GeneDx Chief Financial Officer Kevin Feeley sold 3,729 Class A shares for approximately $227,000 on June 16, 2026, in a transaction tied to the vesting of restricted stock units rather than a discretionary sale. The sale represented 8.54% of Feeley's direct Class A holdings, reducing his position to 39,954 shares, and was executed through a standard sell-to-cover mechanism to satisfy tax withholding obligations. GeneDx reported first-quarter revenue of $102.3 million, up 17% year over year, but lowered its full-year revenue guidance to a top range of $490 million from $555 million. Shares have fallen roughly 27% over the past year, though CEO Katherine Stueland expressed confidence in the company's ability to deliver profitable long-term growth.

SueWallSt reminds investors that a securities class action has been filed against GeneDx Holdings Corp. and the lead plaintiff deadline is August 3, 2026. The lawsuit covers purchasers of WGS stock between April 16, 2025 and May 4, 2026 who lost money. The action alleges that GeneDx leadership knew about Fabric Genomics' deteriorating viability well before disclosing problems, and that positive representations about Fabric were materially false. WGS shares fell 49.20 percent, a loss of $33.42 per share, after the company disclosed a $31.2 million impairment charge tied to Fabric Genomics and cut full-year revenue guidance by approximately $65 million. Investors may contact Joseph E. Levi at SueWallSt for a free evaluation.

Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against GeneDx Holdings Corp. The suit, filed in the United States District Court for the District of Connecticut, covers purchasers of WGS common stock between April 16, 2025 and May 4, 2026. The complaint alleges the company and its executives made false or misleading statements regarding the importance of Fabric Genomics, the durability of average reimbursement rates, and gross margins. On May 4, 2026, GeneDx reported a first-quarter loss of $0.28 per share and a $57.5 million operating loss, lowered its 2026 revenue guidance by approximately $65 million at the midpoint, and took a $31.3 million write-down related to Fabric Genomics. The stock fell roughly 50%, from $67.93 to $34.51, on the news. Investors have until August 3, 2026 to seek lead plaintiff appointment.

A securities fraud class action lawsuit has been filed against GeneDx Holdings Corp. on behalf of investors who purchased or acquired WGS common stock between April 16, 2025, and May 4, 2026. The lawsuit, filed in the United States District Court for the District of Connecticut, alleges that the company made materially false and misleading statements regarding the viability of its acquisition of Fabric Genomics. GeneDx had announced the acquisition on April 16, 2025, in a deal worth up to $51 million, touting Fabric's AI-driven genomic interpretation platform as a source of scalable recurring revenue. On May 4, 2026, the company disclosed a $31.3 million impairment loss directly attributable to Fabric, alongside a drop in adjusted gross margin and lowered earnings projections, causing its share price to fall more than 49%. Investors have until August 3, 2026, to seek lead plaintiff status through Kessler Topaz Meltzer & Check, LLP.

Grabar Law Office is investigating claims on behalf of long-term shareholders of Badger Meter, GeneDx Holdings, GRAIL, and Verra Mobility, concerning whether certain officers and directors breached their fiduciary duties. For Badger Meter, a recently filed federal securities class action alleges that the company attributed strong financial performance to sustainable demand-driven growth while results were materially impacted by pull-forward of customer orders, masking weakening demand trends, and the truth emerged through disappointing quarterly announcements in 2025 and 2026 that caused significant stock declines. For GeneDx, a securities fraud class action alleges that executives made false statements about the Fabric acquisition improving financials and creating efficiencies, when they knew of significant problems in Fabric's viability that would negatively impact the business. For GRAIL, a complaint alleges that officers misled investors about the likelihood that the NHS-Galleri cancer screening trial would meet its primary endpoint, and the stock fell more than 50% in a single day after the company announced on February 19, 2026 that the trial failed to achieve a statistically significant reduction in late-stage cancers. For Verra Mobility, a class action alleges that executives created a false impression about revenue outlook and contract renewals while minimizing risks, and the stock declined approximately 71% after the company announced on May 26, 2026 that it received a termination notice from Avis Budget Group and lowered its full-year 2026 financial outlook. Shareholders who purchased or acquired shares prior to specified dates and still hold them can seek corporate reforms and return of funds at no cost.